STOCK TITAN

Frazier Life Sciences funds report 0% MacroGenics (MGNX) beneficial stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Frazier Life Sciences-affiliated funds and individuals have filed an amended Schedule 13G reporting no beneficial ownership of MacroGenics, Inc. common stock as of December 31, 2025. Each reporting person lists 0 shares beneficially owned and a 0.0% stake in the company’s common stock.

The filing covers multiple Frazier Life Sciences partnerships and LLCs, as well as James N. Topper and Patrick J. Heron, all organized in Delaware or the United States. They certify that any securities referenced were not acquired or held to change or influence control of MacroGenics, but rather on a passive basis.

Positive

  • None.

Negative

  • None.

Insights

Former large holders now report a 0.0% passive stake in MacroGenics.

The filing shows Frazier Life Sciences funds and related individuals collectively reporting 0 shares and a 0.0% beneficial ownership position in MacroGenics, Inc. common stock as of December 31, 2025. This is disclosed via an amended Schedule 13G, which is used for passive holdings.

Item 5 indicates ownership of 5 percent or less of the class, confirming they are no longer 5% holders. The certification also states that any securities were not acquired or held for the purpose of changing or influencing control, emphasizing a non-activist stance.

Future company disclosures may clarify any earlier ownership changes or transactions that led to this 0.0% position, but based on this document alone, the information is limited to current beneficial ownership status and the passive-intent certification.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Frazier Life Sciences Public Fund, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:02/13/2026
FHMLSP, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:02/13/2026
FHMLSP, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:02/13/2026
Frazier Life Sciences X, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:02/13/2026
FHMLS X, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:02/13/2026
FHMLS X, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:02/13/2026
Frazier Life Sciences XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:02/13/2026
FHMLS XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:02/13/2026
FHMLS XI, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:02/13/2026
James N. Topper
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:02/13/2026
Patrick J. Heron
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:02/13/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

What does the Frazier Life Sciences Schedule 13G/A say about MacroGenics (MGNX) ownership?

The amended Schedule 13G states that Frazier Life Sciences-affiliated funds and individuals now report 0 shares and a 0.0% beneficial ownership of MacroGenics common stock as of December 31, 2025, indicating they are no longer 5% holders.

Which entities are the reporting persons in this MacroGenics (MGNX) Schedule 13G/A?

Reporting persons include Frazier Life Sciences Public Fund, multiple Frazier Life Sciences X and XI partnerships and LLCs, FHMLSP and FHMLS entities, and individuals James N. Topper and Patrick J. Heron, all grouped as “Reporting Persons” in the ownership disclosure.

What percentage of MacroGenics (MGNX) does each Frazier reporting person now beneficially own?

Each reporting person lists an aggregate beneficial ownership of 0.00 shares and a percent of class of 0.0%. They also report 0.00 shares for sole or shared voting and dispositive power, confirming no current beneficial ownership position in MacroGenics common stock.

Why was this amended Schedule 13G for MacroGenics (MGNX) required?

The document shows a Date of Event of December 31, 2025, and reports 0.0% beneficial ownership. Item 5 notes ownership of 5 percent or less of the class, which triggers an update when a former significant holder’s stake falls to or below that threshold.

What intent regarding control of MacroGenics (MGNX) is certified in this Schedule 13G/A?

The certification states the securities referenced were not acquired and are not held to change or influence control of MacroGenics. It also notes they are not held in connection with any transaction having that effect, other than activities solely related to a nomination under Rule 14a-11.

Who signed the MacroGenics (MGNX) Schedule 13G/A on behalf of the Frazier entities?

Jennifer Martin signed multiple times, identifying herself as CFO of various FHMLSP and FHMLS LLC general partners and as Attorney-in-Fact for James N. Topper and Patrick J. Heron, under powers of attorney previously filed with the SEC in January 2026.
Macrogenics Inc

NASDAQ:MGNX

MGNX Rankings

MGNX Latest News

MGNX Latest SEC Filings

MGNX Stock Data

108.17M
57.98M
3.25%
80.43%
5.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
Rockville